Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review.
Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves. European studies have addressed its clinical efficacy in treating gastro-oesophageal reflux disease in three areas. 1) Symptom relief: Cisapride, usually at a dose of 10 mg t.i.d., was superior to placebo and metoclopramide in relief of daytime and night-time heartburn and regurgitation. 2) Healing oesophagitis: Six studies showed that cisapride 10 mg q.i.d effectively heals oesophagitis over 6-16 weeks. Cisapride was superior to placebo and as effective as H2-antagonists in healing grades I-III oesophagitis. Combination therapy with H2-antagonists may be superior to H2-blocker alone. 3) Paediatric efficacy: Cisapride 1 mg/kg/day was effective in the treatment of infants and children with oesophagitis and pulmonary symptoms related to acid reflux. In conclusion, cisapride offers a promising alternative for the treatment of gastrooesophageal reflux disease without the troubling side effects of existing promotility drugs.
Richter
J E
JE
Gastroenterology Section, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina 27103.
D000328:Adult; D002648:Child; D020117:Cisapride; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride